NEO-PV-01, a personal neoantigen vaccine, designed based on a patient’s tumor-specific mutations and are predicted to be presented by MHC molecules, is comprised of up to 20 long peptides and administered along with an immune adjuvant Poly-ICLC. The gene discussed is HLA-C; the disease is neoplasm.